Breaking News

VION Biosciences Acquires Echelon Biosciences

By combining forces, VION will be able to offer a more comprehensive suite of products to researchers and developers working on cutting-edge treatments.

Author Image

By: Charlie Sternberg

Associate Editor

VION Biosciences, a life science platform company, has announced the acquisition of Echelon Biosciences, a supplier of critical lipid-based excipients. This strategic move marks the second significant investment for VION under Iron Path Capital’s roll-up platform, solidifying its position in the life science sector.   Echelon’s expertise in lipid synthesis and nanoparticle engineering aligns seamlessly with VION’s focus on mRNA-based therapies. By combining forces, VION will be able to offer a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters